Meeting
2020 ASCO Virtual Scientific Program
Outcome analyses in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with 177Lu-DOTATATE – Impact of treatment order and combination on mortality.
Authors
Alexander Rheinhard Siebenhuener
Klinik für Medizinische Onkologie und Hämatologie, UniversitätsSpital Zürich, Zürich, Switzerland
Alexander Rheinhard Siebenhuener , Dominique Pretot , Valerie Treyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4606)
DOI
10.1200/JCO.2020.38.15_suppl.4606
Abstract #
4606
Poster Bd #
214
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
LANTana trial protocol: An open label, single arm, phase Ib study to evaluate the effect of pre-treatment with ASTX727 (a demethylating agent) followed by lutetium Lu 177 dotatate in patients with progressive, metastatic neuroendocrine neoplasias (NENs).
First Author: Rohini Sharma
Poster
2021 ASCO Annual Meeting
Phase I study of autolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium.
First Author: Timothy Jay Price
Poster
2019 ASCO Annual Meeting
A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium: Cohort 1 results.
First Author: Timothy Jay Price
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Aman Chauhan